China-based IASO Biotechnology has received clinical trial approval from the National Medical Products Administration (NMPA) for its BCMA-directed CAR T cell therapy, Fucaso (equecabtagene autoleucel), now indicated for the treatment of refractory systemic myasthenia gravis (MG).
Originally approved for marketing in China in June 2022 for recurrent and refractory multiple myeloma (MM), Fucaso has also previously secured clinical trial approval for use in neuromyelitis optica spectrum disease (NMOSD). This latest indication marks a significant expansion of Fucaso’s therapeutic applications and underscores IASO’s commitment to advancing innovative treatments in the field of autoimmune disorders.- Flcube.com
